23 Nov

Results of Annual General Meeting

Race Oncology Ltd ABN 61 149 318 749 Registered office: L36, 1 Macquarie Place, Sydney NSW 2000 www.raceoncology.com ASX Announcement Results of Annual General Meeting 23 November 2021 – Race Oncology Limited ( Race or the Company ) (ASX: RAC) advises that its Annual General Meeting of Shareholders was held today at 11.00 am (AEDT). In accordance with Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act 2001 (Cth), the Company advises that the details of the resolutions and the proxies received in respect of each resolution are set out in the attached proxy summary . -ENDS- About Race Oncology (ASX: RAC) Race Oncology is an ASX listed precision oncology company with a Phase 2/3 cancer drug called Zantrene ® . Zantrene is a potent inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein. Overexpression of FTO has been shown to be the genetic driver of a diverse range of cancers. Race is exploring the use of Zantrene as a new therapy for melanoma and clear cell renal cell carcinoma, which are both frequent FTO over-expressing cancers. The Company also has compelling clinical data for the use of Zantrene as a chemotherapeutic agent with reduced cardiotoxicity in Acute Myeloid Leukaemia (AML), breast and ovarian cancers and is investigating its use in these areas. Race is pursuing outsized commercial returns for shareholders via its ‘Three Pillar’ strategy for the clinical development of Zantrene. Learn more at www.raceoncology.com. Release authorised by: Media contact: Phil Lynch, CEO/MD on behalf Jane Lowe of the Race Board of Directors +61 411 117 774 phillip.lynch@raceoncology.com jane.lowe@irdepartment.com.au Disclosure of Proxy Votes Race Oncology Limited Annual General Meeting 2021 Tuesday, 23 November 2021 In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting. Automic GPO Box 5193, Sydney, NSW 2001 P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world) F +61 (0)2 8583 3040 E hello@automic.com.au ABN 27 152 260 814 Proxy Votes Poll Results (if applicable) Resolution Decided by Show of Hands (S) or Poll (P) Total Number of Proxy Votes exercisable by proxies validly appointed FOR AGAINST ABSTAIN PROXY'S DISCRETION FOR AGAINST ABSTAIN 1 Adoption of Remuneration Report P 23,336,291 22,827,379 97.82% 4,600 0.02% 36,497 504,312 2.16% 25,031,347 99.98% 4,600 0.02% 36,497 2 Election of Director – Mary Harney P 42,571,818 42,070,742 98.82% 500 0.00% 72,313 500,576 1.18% 44,269,474 100.00% 2,000 0.00% 72,313 3 Re-election of Director – Dr Daniel Tillett P 42,625,712 42,137,300 98.85% 500 0.00% 18,419 487,912 1.14% 44,324,868 100.00% 500 0.00% 18,419 4 Adoption of Incentive Option Plan P 23,017,714 22,358,654 97.14% 154,167 0.67% 355,074 504,893 2.19% 24,521,082 99.33% 165,161 0.67% 386,201 5 Increase in Total Aggregate Remuneration for Non-Executive Directors P 23,323,382 22,582,573 96.82% 236,247 1.01% 49,406 504,562 2.16% 24,688,170 98.94% 263,741 1.06% 120,533
Information on this Website is provided for general information purposes only and is not a substitute for professional advice. ASX Information (including company announcements and prices) is delayed by at least 20 minutes. JSE Information (including company announcements and prices) is delayed by at least 15 minutes. Reliance on the information you access on or from this Website is solely at your own risk. We make no representation or warranty in relation to the future performance of the companies that appear on this Website. Investment in securities involves risk and you should obtain independent professional legal, financial, investment or company advice before acting on any of the information you access on this Website. Using, browsing or otherwise accessing this Website is subject to our Terms and Conditions and our Privacy Policy.

© 2021 Listcorp. ABN 60 166 140 307

Never miss news from Race Oncology Limited (ASX:RAC) when you join Listcorp.